Samsung投资于AI生物技术公司Generate:Bio Medictures,开发新的疾病蛋白疗法。 Samsung invests in AI biotech firm Generate:Biomedicines to develop new protein therapies for diseases.

Samsung的生命科学基金投资于Generate:Bio Medicals, 一家美国公司使用AI开发新的蛋白质疗法。 Samsung's Life Science Fund has invested in Generate:Biomedicines, a US company that uses AI to develop new protein therapies. 这一投资支持生物制药的创新,侧重于癌症、免疫疾病和感染等领域。 This investment supports innovation in biopharmaceuticals, focusing on areas like cancer, immune diseases, and infections. 产生:Bio Medicals是由旗舰先锋组织创立的,它有20多个正在开发的方案,旨在通过先进技术解决尚未满足的医疗需求。 Generate:Biomedicines, founded by Flagship Pioneering, has over 20 programs in development, aiming to address unmet medical needs through advanced technology.